Dextrose Monohydrate 5% Injection Shortage: Current Availability and Manufacturer Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported an ongoing shortage of Dextrose Monohydrate 5% Injection, with mixed availability across several major pharmaceutical manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dextrose-Monohydrate.
What's in Shortage
As of the latest update, Dextrose Monohydrate 5% Injection (Brand Name: DEXTROSE) is currently listed in shortage. This medication is an injection used across several therapeutic categories, including Endocrinology, Metabolism, Gastroenterology, and Pediatrics. While many presentations remain available, specific product codes from certain manufacturers are currently unavailable or have been discontinued.
Which Manufacturers Are Affected
Several manufacturers supply this medication, with varying levels of availability:
- Baxter Healthcare: Reports mixed availability. While many presentations are available, NDC 0338-0066-20 and NDC 0338-0062-30 are currently unavailable with an estimated availability date to be determined. NDC 0338-9143-30 has been discontinued. (Contact: 888-229-0001)
- Otsuka ICU Medical LLC: All listed presentations are currently available. These products are distributed by ICU Medical. (Contact: 1-866-829-9025 or ProductAvailability@icumed.com)
- B. Braun Medical Inc.: All listed presentations are currently available. (Contact: 800-227-2862)
- Fresenius Kabi USA, LLC: Most presentations are available. However, NDC 65219-464-50 is listed as unavailable, though product with a 3-month expiry (3/31/2026) may be available by request. (Contact: 888-386-1300)
Why There's a Shortage
Specific reasons for the overall shortage were not provided by the FDA. However, Baxter Healthcare noted the discontinuation of the manufacture of one specific presentation (NDC 0338-9143-30). For other unavailable presentations, the estimated recovery dates are currently listed as "To Be Determined."
What Patients Should Do
If you or a family member are prescribed Dextrose Monohydrate 5% Injection, please consider the following steps:
- Consult your healthcare provider: Always speak with your doctor or clinical team regarding your treatment plan and any concerns about medication supply.
- Talk to your pharmacist: Pharmacists have the most up-to-date information on local inventory and can check with various wholesalers.
- Contact manufacturers: If a specific presentation is required, you may use the contact information provided above to inquire about current stock levels.
Disclaimer: Patients should consult their healthcare provider for medical advice and before making any changes to their treatment.
Source
Information provided by the FDA Drug Shortage Database.
Initial Posting Date: 02/14/2022
Last Updated: 02/02/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.